Warner Laura, Chudasama Jessal, Kelly Charles G, Loughran Sean, McKenzie Kenneth, Wight Richard, Dey Paola
Department of Otolaryngology, Head and Neck Surgery,North Manchester General Hospital, Pennine Acute Hospitals NHS Trust, Delaunays Road, Manchester, M8 5RB, UK.
Cochrane Database Syst Rev. 2014 Dec 12;2014(12):CD002027. doi: 10.1002/14651858.CD002027.pub2.
This is an update of a Cochrane review first published in The Cochrane Library in Issue 2, 2002 and previously updated in 2004, 2007 and 2010.Radiotherapy, open surgery and endolaryngeal excision (with or without laser) are all accepted modalities of treatment for early-stage glottic cancer. Case series suggest that they confer a similar survival advantage, however radiotherapy and endolaryngeal surgery offer the advantage of voice preservation. There has been an observed trend away from open surgery in recent years, however equipoise remains between radiotherapy and endolaryngeal surgery as both treatment modalities offer laryngeal preservation with similar survival rates. Opinions on optimal therapy vary across disciplines and between countries.
To compare the effectiveness of open surgery, endolaryngeal excision (with or without laser) and radiotherapy in the management of early glottic laryngeal cancer.
We searched the Cochrane Ear, Nose and Throat Disorders Group Trials Register; the Cochrane Central Register of Controlled Trials (CENTRAL 2014, Issue 8); PubMed; EMBASE; CINAHL; Web of Science; Cambridge Scientific Abstracts; ICTRP and additional sources for published and unpublished trials. The date of the most recent search was 18 September 2014.
Randomised controlled trials comparing open surgery, endolaryngeal resection (with or without laser) and radiotherapy.
We used the standard methodological procedures expected by The Cochrane Collaboration.
We identified only one randomised controlled trial, which compared open surgery and radiotherapy in 234 patients with early glottic laryngeal cancer. The overall risk of bias in this study was high.For T1 tumours, the five-year survival was 91.7% following radiotherapy and 100% following surgery and for T2 tumours, 88.8% following radiotherapy and 97.4% following surgery. There were no significant differences in survival between the two groups.For T1 tumours, the five-year disease-free survival rate was 71.1% following radiotherapy and 100.0% following surgery, and for the T2 tumours, 60.1% following radiotherapy and 78.7% following surgery. Only the latter comparison was statistically significant (P value = 0.036), but statistical significance would not have been achieved with a two-sided test.Data were not available on side effects, quality of life, voice outcomes or cost.We identified no randomised controlled trials that included endolaryngeal surgery. A number of trials comparing endolaryngeal resection and radiotherapy have terminated early because of difficulty recruiting participants. One randomised controlled trial is still ongoing.
AUTHORS' CONCLUSIONS: There is only one randomised controlled trial comparing open surgery and radiotherapy but its interpretation is limited because of concerns about the adequacy of treatment regimens and deficiencies in the reporting of the study design and analysis.
这是一篇Cochrane系统评价的更新内容,该评价首次发表于《Cochrane图书馆》2002年第2期,此前于2004年、2007年和2010年进行过更新。放射治疗、开放手术和喉内切除术(无论是否使用激光)都是早期声门型喉癌公认的治疗方式。病例系列研究表明,它们具有相似的生存优势,然而放射治疗和喉内手术具有保留嗓音的优势。近年来,已观察到一种远离开放手术的趋势,然而放射治疗和喉内手术之间仍存在平衡,因为这两种治疗方式都能保留喉部且生存率相似。不同学科和国家对于最佳治疗方案的意见各不相同。
比较开放手术、喉内切除术(无论是否使用激光)和放射治疗在早期声门型喉癌治疗中的有效性。
我们检索了Cochrane耳、鼻、喉疾病组试验注册库;Cochrane对照试验中心注册库(CENTRAL 2014年第8期);PubMed;EMBASE;CINAHL;科学引文索引;剑桥科学文摘;国际临床试验注册平台以及其他已发表和未发表试验的来源。最近一次检索日期为2014年9月18日。
比较开放手术、喉内切除术(无论是否使用激光)和放射治疗的随机对照试验。
我们采用了Cochrane协作网预期的标准方法程序。
我们仅识别出一项随机对照试验,该试验比较了234例早期声门型喉癌患者的开放手术和放射治疗。本研究中总体偏倚风险较高。对于T1期肿瘤,放射治疗后的五年生存率为91.7%,手术治疗后为100%;对于T2期肿瘤,放射治疗后为88.8%,手术治疗后为97.4%。两组之间的生存率无显著差异。对于T1期肿瘤,放射治疗后的五年无病生存率为71.1%,手术治疗后为100.0%;对于T2期肿瘤,放射治疗后为60.1%,手术治疗后为78.7%。只有后一项比较具有统计学意义(P值 = 0.036),但双侧检验不会得出统计学意义。关于副作用、生活质量、嗓音结果或成本的数据不可用。我们未识别出纳入喉内手术的随机对照试验。一些比较喉内切除术和放射治疗的试验因招募参与者困难而提前终止。一项随机对照试验仍在进行中。
仅有一项比较开放手术和放射治疗的随机对照试验,但其解释受到限制,因为担心治疗方案的充分性以及研究设计和分析报告中的缺陷。